Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients

被引:12
作者
Almirall, J
Lopez, TS
Vallve, M
Ruiz, A
Llibre, J
Betriu, A
机构
[1] UAB, Nephrol Unit, Corp Sanitaria Parc Tauli, Inst Univ Parc Tauli, ES-08208 Sabadell, Spain
[2] CETIRSA, Terrassa, Spain
[3] Sistemes Renals, Lleida, Spain
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 97卷 / 01期
关键词
hyperphosphataemia; dialysis; phosphate binders; cholesterol; sevelamer;
D O I
10.1159/000077591
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: The treatment of hyperphosphataemia is of major importance in the management of patients on dialysis. Traditional phosphate binders can be associated with undesirable effects. Recently, a new non-absorbable phosphate-binding polymer, sevelamer hydrochloride, has been available. Clinical information is scarce, and its cost could be a limiting factor for its wider use. No studies have evaluated its usefulness in uncontrolled hyperphosphataemic patients. Methods: We identified 34 patients with a maintained serum phosphorus concentration 16.5 mg/dl and/or toxicity related to standard phosphorus-binding treatment (aluminium or calcium based). Sevelamer was added and titrated up fortnightly to achieve phosphorus control. Previous phosphate binders were decreased, whenever possible. The period of the study was 6 months. Results: Thirteen patients (38%) dropped out because of side effects, mainly related to the gastro-intestinal tract. The efficacy analysis disclosed that the phosphorus concentration decreased from 2.39+/-0.48 to 1.84+/-0.48 mmol/l (p<0.001). The mean dose of sevelamer was stabilised at 3.4 +/- 1.8 g/day. The amount of calcium- and aluminium-based phosphate binders could be decreased from 5.1 +/- 3.5 to 3.1 +/- 2.7 g/day (38% decrease) and from 2.4 +/- 1.5 to 1.5 +/- 1.7 g/day (36% decrease), respectively. The Ca x P product was significantly decreased from 5.83 +/- 1.19 to 4.36 +/- 1.12 mmol/l(2) (p<0.001). The total cholesterol concentration decreased from 4.34+/-0.9 to 3.98+/-0.9 mmol/l (p<0.01) and the low-density lipoprotein cholesterol level from 2.61 +/- 0.98 to 2.20 +/- 0.77 mmol/l (p<0.03). Conclusions: Sevelamer is an effective phosphate binder that allows a better serum phosphorus control, while allowing a decrease in the dose of calcium- and aluminium-based phosphate binders in these difficult patients. The drawbacks are the high intolerance rate and the price of the product. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C17 / C22
页数:6
相关论文
共 33 条
[11]   Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure [J].
Chertow, GM ;
Burke, SK ;
Lazarus, JM ;
Stenzel, KH ;
Wombolt, D ;
Goldberg, D ;
Bonventre, JV ;
Slatopolsky, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (01) :66-71
[12]   Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Dillon, MA ;
Slatopolsky, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) :2907-2914
[13]   HYPERPHOSPHATEMIA - ITS CONSEQUENCES AND TREATMENT IN PATIENTS WITH CHRONIC RENAL-DISEASE [J].
DELMEZ, JA ;
SLATOPOLSKY, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (04) :303-317
[14]  
FOURNIER A, 1986, KIDNEY INT, pS114
[15]   Effect of RenaGel®, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients [J].
Goldberg, DI ;
Dillon, MA ;
Slatopolsky, EA ;
Garrett, B ;
Gray, JR ;
Marbury, T ;
Weinberg, M ;
Wombolt, D ;
Burke, SK .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (09) :2303-2310
[16]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483
[17]   Arterial stiffening and vascular calcifications in end-stage renal disease [J].
Guérin, AP ;
London, GM ;
Marchais, SJ ;
Metivier, F .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (07) :1014-1021
[18]   BONE ALUMINUM AND HISTOMORPHOMETRIC FEATURES OF RENAL OSTEODYSTROPHY [J].
HODSMAN, AB ;
SHERRARD, DJ ;
ALFREY, AC ;
OTT, S ;
BRICKMAN, AS ;
MILLER, NL ;
MALONEY, NA ;
COBURN, JW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (03) :539-546
[19]   Are we mismanaging calcium and phosphate metabolism in renal failure? [J].
Hsu, CH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (04) :641-649
[20]   GASTROINTESTINAL ABSORPTION OF ALUMINUM FROM ALUMINUM-CONTAINING ANTACIDS [J].
KAEHNY, WD ;
HEGG, AP ;
ALFREY, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (24) :1389-1390